Current board member and advisor for several biotech companies, Gilles Avenard is Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to their official registration on both European and North-American territories. Before that, he worked as Project Director for Hoechst Marion Roussel (Sanofi) and was Medical Director of Bio-Transfusion (LFB).
Office Manager
Nacera Brouttelande
After an extensive professional experience at a court-appointed representative’s office in Paris, Nacera Brouttelande joined Acticor Biotech in June 2018 where she works as office manager notably dealing with the company’s administrative, legal and accounting follow-up.
Medical Director
Andrea Comenducci
Andrea Comenducci, MD, Medical Director at Acticor Biotech. Educated as a General Practitioner, Andrea has a 25-year experience in the pharmaceutical industry. He assumed various functions from International Project leader and Senior Medical Advisor to Medical Director in medium and large companies. His preferred therapeutic area is the cardiovascular field in which he has vast experience in coronary diseases, high blood pressure, heart failure, atherosclerosis acquired in large worldwide clinical trials such as the GUSTO V-TIMI 14 study, STABILITY and SOLID-TIMI 52 studies. In November 2018, Andrea joined Acticor Biotech with the role of Medical Director in order to take up new exciting challenges in acute ischemic stroke and pulmonary embolism.
Chief Financial Officer
Eric Cohen
CEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies (among which EOS imaging, Cellnovo, PKvitality), Eric raised over 200M€ in public and private fund raising. He was previously CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV). He led 2 IPO on Euronext® raising 62M€. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea Technologies.
CMC Adviser
Olivier Favre-Bulle
Founder of 3Biotech, Olivier Favre-Bulle specializes in Pharmaceutical Development of Large and Small Molecules. After a Ph.D in Bioengineering, he started his career as project manager in Biological Drugs development at Rhône-Poulenc. He was site manager and European Head of Drug Development for Covance, and he also directed the NNE Pharmaplan France, a subsidiary of Novo Nordisk.
Analytical Project Manager
Pauline Ferlan
With a professional bachelor’s degree in pharmaceutical industries, focusing on biotechnology. P. Ferlan started her career in Sanofi’s R&D laboratories. She works on analytical methods development, stability studies and functional characterization of ACT017.
Financial and Administrative Manager
Aymeric Humblot
With a Master’s degree in Accounting and Finance, Aymeric was an Audit Manager at Grant Thornton for 7 years. He worked on listed and non-listed companies and specialized in the Biotech industry. He joined Acticor Biotech in January 2019 as Administrative and Finance Manager.
Head of Regulatory Affairs and Quality
Laurie Jullien
PharmD., Master in International Drug Development and Registration. Laurie Jullien started at Genentech (USA) in Product Drug Development and was then appointed Regulatory Affairs Labelling Manager at Roche (UK). She joined Acticor Biotech in 2016 and started as Regulatory and Quality Manager, working from the non-clinical studies to the Phase 1 trial and Scientific Advices, before being promoted Head of Regulatory Affairs and Quality in 2018. She now ensures the Regulatory Direction and the development of the Quality Policy of the company.
Pharmaceutical Development Associate
Angéla La
With a Master degree of Biotechnology Engineering from Sup’Biotech and a PhD in Bioprocess Enginneeing from CentraleSupélec school (previously Centrale Paris), Angéla started her career in the development and optimisation of cell culture in bioreactor within the Chair of Biotechnology of CentraleSupélec. She joined Acticor Biotech in March 2020 as Pharmaceutical Development Associate.
Chief Operating Officer and Chief Scientific Officer
Sophie Lebel-Binay
Sophie has over 20 years’ experience in start-ups and mid-size companies within the biotechnology areas. She has a strong expertise in oncology, immunology and virology. Sophie has managed a number of innovative R&D projects from the proof-of-concept to early clinical development. In her previous positions, Sophie was Vice-President Research and Early Clinical Development at PEP-Therapy, responsible for the development of peptide drug candidates and their biomarkers up to clinical trials. She was responsible for nonclinical R&D activities at InnaVirVax, developing innovative immune-based treatments for infectious diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center, where she coordinated research programs and implemented innovative technology platforms dedicated to translational research. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, VIRalliance and Stallergenes. Sophie holds a PhD in immunology from Paris VII Denis Diderot university. She is (co-)author of about 20 scientific publications and co-inventor of 9 patents.
Head of Pharmaceutical & Non-Clinical Development
Kristell Lebozec
Master degree of Biotechnology Engineering with a focus on R&D and Health, Kristell Lebozec has a 2 years experience in academic laboratories (Institut Gustave Roussy and Centre de Recherche des Cordeliers) and in the industry (DNA Therapeutics and I-Stem). She joined Acticor Biotech in 2015 and was in charge of selecting ACT017 expression system and of the functional characterization of product. She is now managing the pharmaceutical and non-clinical development.
Global Clinical Operations Director
Adeline Meilhoc
Adeline Meilhoc has spent her career in the clinical development of pharmaceutical products in pharmaceutical companies and contract research organizations – UCB Pharma, Parexel Inc., Cegedim Sgtrategic Data, both as VP Medical Affairs and Clinical Operations and as VP Business Development. She has built several departments in clinical trial feasibility, study start-up and medical imaging as well as commercial and marketing development.
Specializing in business relationships, she has spent the last few years developing Marketing & Sales strategies in various eClinical tools for Healthcare Professionals and Medical Device companies, in addition to her own businesses. Her solid expertise in Real World Evidence and in the operational aspect of market access broadens her vision of drug development and launch. She is a clinical psychologist by training at the ICP – EPP where she obtained a thesis in addiction and depression with honors. She brings now her expertise to Acticor Biotech in the direction of clinical trials and team management.
Chief Medical Officer
Yannick Plétan
Dr Plétan is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre. Before joining Acticor Biotech, Dr Plétan served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland). Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer.
Quality Assurance Manager
Victoria Rutman
PharmD. – Master in Quality Assurance – Pharmaceutical Products.
Victoria Rutman has 3 years of hands-on experience in the pharmaceutical industry. Primarily, at Orphan Europe, she worked in the Quality Assurance Department before being promoted as a Packaging and Equipment project manager.
She is in charge of the Quality system management at Acticor.
Clinical Operations Manager
Rassa Pegahi
Rassa has more than twelve years of experience in clinical research & medical affairs management. Her basic researches focused on Alzheimer disease as well as onco-hemato-pediatrics pathologies and stem cells. After she completed her Ph.D. in Cell & Molecular Biology from the University of Rouen, she passed the clinical research manager diploma from the medical school, University of Paris-Descartes. Rassa supervised more than 30 French and International trials in different therapeutic domains such as Oncology, Urology, Vascular access, Dermatology, Phlebology, ICU, Geriatrics, Plastic Surgery. She has a very good knowdedge of hospital environment and worked several years for both French and American multinational pharmaceutical labs, before joining Acticor to supervise Clinical operations.
Regulatory and Clinical Associate
Jessica Jami
After a master degree in pharmaceutical biotechnology and innovative therapy, Jessica (PharmD) joined Acticor Team in November 2019 as Regulatory and Clinical Associate after completing her end of study internship in Regulatory Affairs and CMC departments. She monitors and participates in regulatory activities of clinical projects.
Clinical Operations Trainer
Stéphanie PAUL
Stéphanie PAUL, Clinical Research Nurse Trainer at Acticor Biotech, background of study research nurse; she has more than 13 years of experience in a clinical research center in CHRU from Brest.
She assumed various functions from study coordinator in different therapeutic domains: respiratory, thromboembolic diseases, vascularitis and neurological area. She supervised both French and international trials, and realized all the technical care, in respect of GCP.
She comes from hospital so she could be a veritable resource for the training staff.
